Indivior Pharmaceuticals (INDV) Operating Expenses (2024 - 2026)

Indivior Pharmaceuticals has reported Operating Expenses for 3 years, with the latest figure at $134.0 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 25.14% year-over-year to $134.0 million in Q2 2026; TTM through Jun 2026 was $671.0 million, a 10.05% decrease from a year earlier, with the FY2025 full-year figure at $732.0 million, down 20.35% from the prior year.
• Operating Expenses was $134.0 million for Q2 2026 at Indivior Pharmaceuticals, down from $139.0 million in the prior quarter.
• The five-year high for Operating Expenses was $338.0 million in Q2 2024, with the low at $134.0 million in Q2 2026.
• Average Operating Expenses over 3 years is $192.6 million, with a median of $183.0 million recorded in 2025.
• The largest YoY upside for Operating Expenses was 2.93% in 2025 against a maximum downside of 47.04% in 2025.
• Over 3 years, Operating Expenses stood at $205.0 million in 2024, then increased by 2.93% to $211.0 million in 2025, then slumped by 36.49% to $134.0 million in 2026.
• The last three Operating Expenses figures came in at $134.0 million (Q2 2026), $139.0 million (Q1 2026), and $211.0 million (Q4 2025), per Business Quant data.